According to a recent LinkedIn post from Truveta, new research conducted with SK Life Science, Inc. suggests that seizure frequency can be extracted at scale from unstructured clinical notes using the Truveta Language Model. The post indicates that this approach targets a key epilepsy outcome measure that is often not captured in standard EHR fields.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights a Neurology journal study of 2,480 patients treated with cenobamate, in which the model reportedly identified seizure counts, frequency, and temporal changes to build longitudinal patient timelines. The post notes a 97% high-confidence extraction rate across varied clinical note types, suggesting potential robustness of the method.
From an investor perspective, the post points to expanding real-world data capabilities that could increase the value proposition of Truveta’s analytics platform for life sciences and healthcare customers. Enhanced ability to mine unstructured notes may support more detailed effectiveness and safety studies, potentially strengthening Truveta’s competitive position in real-world evidence and AI-enabled clinical insights.
If adopted broadly by biopharma and medical device companies, such capabilities could translate into higher demand for Truveta’s data products and partnerships. The collaboration with SK Life Science, Inc. and publication in a peer-reviewed journal may also add credibility to Truveta’s technology, which could be relevant for future commercialization, pricing power, and long-term revenue opportunities in the healthcare data market.